Best Peptide Stack for Fat Loss
Fat loss peptides attack body composition from multiple angles: GLP-1 agonists crush appetite, GH secretagogues mobilize fat, and mitochondrial enhancers boost metabolic rate. Stacking accelerates results while preserving muscle.
Build Your Fat Loss StackFat Loss Subcategories
Appetite Control
Satiety signaling, craving reduction
View best peptides →Metabolic Rate
Basal metabolism, thermogenesis, energy expenditure
View best peptides →Visceral Fat
Targeting deep abdominal fat stores
View best peptides →Body Recomposition
Simultaneous fat loss and muscle preservation
View best peptides →Top Peptides for Fat Loss
Semaglutide
Active ingredient in Ozempic/Wegovy. Mimics GLP-1 to signal fullness and slow gastric emptying. STEP trials showed 14.9% weight loss at 68 weeks.
Tirzepatide
Active ingredient in Mounjaro/Zepbound. Dual GLP-1/GIP agonist — more effective than semaglutide. SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks.
Retatrutide
Next-gen triple agonist from Eli Lilly hitting GLP-1, GIP, and glucagon receptors. Phase 2 showed 24.2% weight loss at 48 weeks — highest of any incretin therapy. At low doses, optimizes metabolism without major weight loss.
CagriSema
Semaglutide + cagrilintide combo in Phase 3 trials. Strongest weight loss data of any injectable to date, surpassing semaglutide alone through dual appetite/satiety targeting.
Survodutide
Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim. The glucagon component adds liver fat reduction, promising for fatty liver disease alongside obesity.
Mazdutide
Dual GLP-1/glucagon receptor drug from Innovent Biologics. Strong weight loss and metabolic results. Already approved in China for obesity.
Orforglipron
First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.
Tesamorelin
FDA-approved GH booster for reducing visceral belly fat in HIV-associated lipodystrophy. Trials showed ~15-18% visceral fat reduction. Overall weight loss is modest vs GLP-1 agonists.
MOTS-c
Mitochondrial DNA-encoded peptide that activates AMPK, improving insulin sensitivity, fat burning, and mimicking exercise at the cellular level. Stacks well with SS-31 and NAD+.
Proven Synergy Stacks for Fat Loss
Mitochondrial-axis overlap. SS-31 binds cardiolipin to stabilize inner-membrane structure; NAD+ is the redox substrate for sirtuin and electron-transport flux. Together they target the same organelle through complementary nodes (structure + cofactor pool).
GHRH × GHRP convergence on the somatotroph. CJC-1295 (GHRH analog) primes the pituitary; ipamorelin (selective GHRP) triggers GH release without ACTH or prolactin elevation.
AMPK convergence at different tiers. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors (Phase 2 NEJM 2023, N=338); MOTS-c is a mitochondrial-derived peptide that upregulates AMPK and GLUT4 translocation in muscle. Hormone-axis × intracellular-energy-sensor pair.
GLP-1/GIP/glucagon triple-receptor signaling combined with NAD+ as substrate for sirtuin-driven lipid oxidation gene expression. Hormonal-axis × cofactor-pool pair.
Triple-incretin receptor signaling combined with mitochondrial-membrane stabilization. Hormonal-axis × organelle-structure pair — Phase 3 retatrutide trials ongoing; SS-31 Phase 3 MMPOWER-3 missed primary endpoint.
GH-axis pairing. Tesamorelin is an FDA-approved GHRH analog (HIV-associated lipodystrophy indication); AOD-9604 is a GH C-terminal fragment with lipolytic activity in preclinical models (Phase IIb missed obesity endpoint).
Ready to Build Your Fat Loss Stack?
Our AI stacker picks the optimal peptides for your goals and budget, with synergy scoring and dosing protocols.
Build Your Stack — It's Free